The collaboration will provide pharmaceutical companies with a global liquid biopsy CDx test
Myriad Genetics, a specialist in molecular diagnostic testing and precision medicine, and Sophia Genetics, an AI technology company focused on precision medicine, have formed a strategic collaboration to develop and provide pharmaceutical companies with a global liquid biopsy companion diagnostic (CDx) test.
The partnership will utilise Myriad's laboratory capabilities in the US as a foundation for the global testing of clinical trials and Sophia Genetics' network of over 800 connected institutions in more than 70 countries for global test deployment.
Sam Raha, president and CEO, Myriad Genetics, said, "Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics. We expect this collaboration with Sophia Genetics to support the development and global commercialisation of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu and support the growth of our CDx programs."
The partnership will first focus on the liquid biopsy application, MSK-Access, powered by Sophia DDM, a liquid biopsy test developed in collaboration with Memorial Sloan Kettering Cancer Centre. It detects actionable genomic alterations from a single blood draw using proprietary algorithms to analyse circulating tumour data (ctDNA). Developing the application into a CDx enables more patients to gain access to the benefits of the tumour profiling test.
Myriad will pursue regulatory submissions in the US, and Sophia Genetics will oversee regulatory submissions outside of the US. Both companies will collaborate across development activities. This hybrid approach aims to provide pharmaceutical partners with access to key regulated markets globally.
Jurgi Camblong, co-founder and CEO of Sophia Genetics, said, "This collaboration represents a pivotal moment for the industry. By combining the complementary strengths of a speciality lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics. This collaboration will allow us to serve both clinical and pharmaceutical partners better, while accelerating the adoption of liquid biopsy solutions across key markets."
